Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Oncolytics Biotech ( (TSE:ONC) ) is now available.
Oncolytics Biotech Inc. announced it will host a key opinion leader webinar on July 22, 2025, to discuss the potential of pelareorep in treating metastatic pancreatic ductal adenocarcinoma and other gastrointestinal cancers. The event will feature notable experts in the field and aims to highlight pelareorep’s existing clinical data and its potential as an immunotherapy. This initiative underscores Oncolytics’ commitment to advancing cancer treatment and could strengthen its position in the oncology market, potentially impacting stakeholders by showcasing the therapeutic’s capabilities and future prospects.
The most recent analyst rating on (TSE:ONC) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the TSE:ONC Stock Forecast page.
Spark’s Take on TSE:ONC Stock
According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.
Oncolytics Biotech faces significant financial challenges with persistent operational losses and reliance on external funding. Although technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The valuation reflects the speculative nature of biotech investments, with no revenue and negative P/E. Recent earnings call and corporate events offer potential upside through strategic developments but are overshadowed by leadership transitions and market value concerns. Overall, the stock remains speculative with potential upside contingent on successful clinical outcomes.
To see Spark’s full report on TSE:ONC stock, click here.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company is advancing its research in oncology, particularly in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. Pelareorep has shown promising results in clinical trials by inducing anti-cancer immune responses and enhancing the efficacy of existing oncology treatments.
Average Trading Volume: 177,081
Technical Sentiment Signal: Buy
Current Market Cap: C$151M
See more insights into ONC stock on TipRanks’ Stock Analysis page.